How to Read an Animal Study About Peptides

Start with the claim you want to check

Write down the claimed human outcome first: for example, faster recovery from a particular injury. Then compare it with what the animal experiment actually measured. Mechanism, biomarker change, tissue appearance, and functional recovery are different outcomes. An animal result is evidence about the studied species, model, route, and outcome; it does not by itself show human benefit (van der Worp et al.).

Check what the paper reports

The ARRIVE 2.0 guidelines provide a reporting framework for animal research. Use these questions when reading the methods and results:

1. What was the experimental unit? Check the species, strain, sex, age, disease model, number of animals, and number assigned to each group. A count of measurements is not necessarily a count of independent animals.
2. What was compared? Identify the control group, route, treatment timing, and the exact primary outcome. Look for a justified sample size and a predefined analysis plan.
3. How was bias limited? Check whether allocation was randomized, whether outcome assessors were blinded, and whether exclusions or missing observations were reported.
4. How complete are the results? Look for results for every group, effect sizes with variability, adverse events, and any differences between planned and reported outcomes.
5. Does the model fit the human claim? Compare the modeled disease, treatment setting, and endpoint with the people and outcome in the claim. An animal experiment may answer a useful mechanism question while leaving the clinical question open (van der Worp et al.).

ARRIVE is a reporting guideline. A paper that reports all these details can still have bias or limited relevance to humans; a missing detail makes independent assessment harder. Its checklist is not a clinical validation score.

Then look for the matching human evidence

Ask whether a human study used the same compound, route, condition, and outcome. A registry entry is a plan, not a result. An uncontrolled report can describe what happened to participants, but without a comparison group it cannot isolate a treatment effect. A broad translation percentage cannot answer this compound-specific question; the 2024 umbrella review pooled different interventions and diseases rather than estimating a peptide’s chance of success.

For example, as of September 2026, a two-person BPC-157 IV pilot reported short-term tolerability and selected laboratory measures, while an uncontrolled 12-person bladder-symptom report used local injections. Neither study tested whether BPC-157 repairs a muscle or tendon injury, and neither establishes safety for other routes. Evidence grade for inferring a human injury-recovery benefit from animal findings alone: very low.

For the denominators and limitations behind published translation percentages, read the animal-to-human translation analysis.

This checklist is for evaluating research claims, not for treatment decisions or medical advice.

Sources & Citations

• 1

  journal

  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research

  pmid-32663219

• 2

  journal

  Can animal models of disease reliably inform human studies?

  pmid-20361020

• 3

  journal

  Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications

  pmid-38870090

• 4

  journal

  Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

  pmid-40131143

• 5

  journal

  Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study

  pmid-39325560